logo-loader
viewTekcapital PLC

Belluscura Files Additional Patent

/**/ sup{font-size:80%}p{margin-top:5.0pt;margin-right:0cm;margin-bottom:5.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .at{size:612.0pt 792.0pt;margin:36.0pt 36.0pt 36.0pt 36.0pt;}div.at{}p.ci{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;border:none;font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}p.cj{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;border:none;font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center; text-autospace: none}span.cf{color:black}p.ck{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;border:none;font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify; text-autospace: none}p.cl{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}span.cc{font-size: 10.0pt;font-family:"Arial","sans-serif"}p.cm{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;line-height: normal; margin-bottom: 0cm; text-align: center}span.ca{font-size:10.0pt} p.cn{margin-top:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;border:none;margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify}span.by{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.bw{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.co{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:black;border:none;margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify; line-height:normal}p.bu{ font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: justify}p.bt{margin:0cm;margin-bottom:.0001pt;text-align:justify;background:white}p.cp{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;border:none;font-weight: bold; line-height: normal; margin-bottom: 0cm}table.cq{width:486.9pt;margin-left:-10.8pt;border-collapse:collapse}tr.bl{height:30.3pt}td.bp{width:158.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:30.3pt} p.cr{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;border:none;font-weight: bold; margin-bottom: 0cm}p.cs{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;border:none;margin-bottom:0cm;margin-bottom:.0001pt}td.bm{width:307.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:30.3pt}p.ct{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;border:none;font-weight: bold; margin-bottom: 0cm; text-align: right}p.cu{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;border:none;margin-bottom: 0cm; text-align: right}tr.bi{height:11.85pt}td.bk{width:158.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:11.85pt}td.bj{width:307.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:11.85pt}tr.bf{height:11.4pt}td.bh{width:158.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:11.4pt} td.bg{width:307.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:11.4pt}td.be{width:318.1pt;padding:0cm 0cm 0cm 0cm; height:11.85pt}td.bd{width:141.2pt;padding:0cm 0cm 0cm 0cm; height:11.85pt}td.bc{width:176.9pt;padding:0cm 0cm 0cm 0cm; height:11.85pt}p.cv{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;border:none;margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify}p.cw{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;border:none;font-weight: bold; margin: 0cm; margin-bottom: .0001pt}span.az{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}p.cx{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;border:none;margin:0cm;margin-bottom:.0001pt;text-align:justify}span.aw{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}p.cy{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;border:none;margin:0cm;margin-bottom:.0001pt} p.cz{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext;border:none;font-weight: bold; margin-bottom: 0cm; margin-left: 0cm; margin-right: -29.4pt; margin-top: 0cm; text-align: justify} /**/
RNS Number : 4751Q
Tekcapital plc
19 February 2019
 

19th February 2019

Tekcapital plc

("Tekcapital" or the "Company")

 

Belluscura Files Additional Patent

 

 

Tekcapital plc (AIM: TEK), the UK intellectual property (IP) investment group focused on creating marketplace value from university technology, announces that its portfolio company Belluscura plc ("Belluscura") in conjunction with its exclusive research partner Separation Design Group, has expanded its oxygen therapy technology with the filing of a broad patent application covering oxygen enrichment inventions relating to a portable artificial lung and wound care devices.

 

The latest patent application, titled "Improved Extracorporeal Membrane Oxygenation Device, System and Related Methods," involves incorporating and expanding their existing oxygen enrichment patent portfolio into an innovative, next generation portable artificial lung and a novel wound care treatment device.

 

Commenting on the patenting activities, Bob Rauker, CEO of Belluscura, said: "We are very excited about our next generation oxygen technology.  With the anticipated launch of our X-PLOR™ portable oxygen concentrator later this year into the respiratory treatment field where over 250 million people suffer from chronic obstructive pulmonary disease (COPD), the third leading cause of death, it is critical that we continue to innovate into the ever-expanding oxygen therapy market."

 

Dr. Clifford Gross, Chairman at Tekcapital commented: "We are delighted to see the continued progress of Belluscura."

 

About Belluscura

Belluscura (www.belluscura.com) was established by Tekcapital with the objective of improving healthcare through innovation.  They are currently developing a proprietary oxygen concentrator system with a planned commercial release in 2019 that will be used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions such as COPD, asthma, occupational lung diseases and pulmonary hypertension. Tekcapital owns approximately 29% of Belluscura.

 

For further information, please contact:

Tekcapital plc

Clifford M Gross, Ph.D.

Via Yellow Jersey PR

 

finnCap Ltd (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7220 0500

Geoff Nash / Max Bullen-Smith (Corporate Finance)


Camille Gochez/Alice Lane (ECM)


Novum Securities Limited (Joint Broker)

+44 (0) 20 7399 9427

Colin Rowbury (Corporate Broking)


Yellow Jersey Limited

+44 (0) 20 7933 8780

Tim Thompson / Annabel Atkins


[email protected]

 

 

 

Tekcapital plc - The World's Largest University Network for Open Innovation

 

Tekcapital's objective is to create value from investing in new, university-developed intellectual properties. Additionally, using its proprietary discovery search engine, linked to 4,500+ universities in 160 countries, coupled with expert scientific review, Tekcapital provides a range of IP investment services to make it easy for organisations to find, evaluate, acquire and license university-developed technology. Tekcapital plc is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com

 

LEI: 213800GOJTOV19FIFZ85

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAGGUMCPUPBURB

Quick facts: Tekcapital PLC

Price: 5.95

Market: LSE
Market Cap: £3.79 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tekcapital PLC reports 'successful half year' with record revenue and profit

Tekcapital PLC's (LON:TEK) Clifford Gross tells Proactive London the six months to the end of May 2019's been a successful half-year for the business. The intellectual property (IP) group that specialises in commercialising university technology, saw its net assets increase by 27% to...

on 23/8/19